MX2024008500A - Construcciones multiespecíficas y usos de estas. - Google Patents
Construcciones multiespecíficas y usos de estas.Info
- Publication number
- MX2024008500A MX2024008500A MX2024008500A MX2024008500A MX2024008500A MX 2024008500 A MX2024008500 A MX 2024008500A MX 2024008500 A MX2024008500 A MX 2024008500A MX 2024008500 A MX2024008500 A MX 2024008500A MX 2024008500 A MX2024008500 A MX 2024008500A
- Authority
- MX
- Mexico
- Prior art keywords
- cldn6
- antibodies
- signaling
- multispecific constructs
- expressing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022070870 | 2022-01-09 | ||
| CN2022117334 | 2022-09-06 | ||
| PCT/CN2023/071334 WO2023131329A1 (en) | 2022-01-09 | 2023-01-09 | Multispecific constructs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008500A true MX2024008500A (es) | 2024-08-26 |
Family
ID=87073282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008500A MX2024008500A (es) | 2022-01-09 | 2023-01-09 | Construcciones multiespecíficas y usos de estas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250074995A1 (enExample) |
| EP (1) | EP4460527A4 (enExample) |
| JP (1) | JP2025501372A (enExample) |
| KR (1) | KR20240133746A (enExample) |
| CN (1) | CN119173539A (enExample) |
| AU (1) | AU2023205989A1 (enExample) |
| CA (1) | CA3248088A1 (enExample) |
| MX (1) | MX2024008500A (enExample) |
| WO (1) | WO2023131329A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| US11739136B2 (en) * | 2019-03-18 | 2023-08-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Inducible dominant negative PD-1 and uses in adoptive cell therapy |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| PH12022552323A1 (en) * | 2020-03-31 | 2023-12-04 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| EP4138864A4 (en) * | 2020-04-23 | 2024-07-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Polyspecific binding molecules and their use in cell therapy |
| WO2021247474A1 (en) * | 2020-06-02 | 2021-12-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Sstr-binding chimeric antigen receptors |
| CN117355540A (zh) * | 2021-05-21 | 2024-01-05 | 百济神州有限公司 | 抗cd137抗体和使用方法 |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
-
2023
- 2023-01-09 MX MX2024008500A patent/MX2024008500A/es unknown
- 2023-01-09 CA CA3248088A patent/CA3248088A1/en active Pending
- 2023-01-09 CN CN202380024591.3A patent/CN119173539A/zh active Pending
- 2023-01-09 EP EP23737191.9A patent/EP4460527A4/en active Pending
- 2023-01-09 WO PCT/CN2023/071334 patent/WO2023131329A1/en not_active Ceased
- 2023-01-09 KR KR1020247026895A patent/KR20240133746A/ko active Pending
- 2023-01-09 US US18/727,561 patent/US20250074995A1/en active Pending
- 2023-01-09 JP JP2024541042A patent/JP2025501372A/ja active Pending
- 2023-01-09 AU AU2023205989A patent/AU2023205989A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023131329A1 (en) | 2023-07-13 |
| CN119173539A (zh) | 2024-12-20 |
| EP4460527A4 (en) | 2026-03-11 |
| JP2025501372A (ja) | 2025-01-17 |
| CA3248088A1 (en) | 2023-07-13 |
| EP4460527A1 (en) | 2024-11-13 |
| KR20240133746A (ko) | 2024-09-04 |
| US20250074995A1 (en) | 2025-03-06 |
| AU2023205989A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211147A1 (es) | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso | |
| MX2021010441A (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. | |
| ES2579554T3 (es) | Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos | |
| CO2021014566A2 (es) | Compuestos y conjugados de estos | |
| CO2023015593A2 (es) | Terapias basadas en il2 y métodos de uso de las mismas | |
| SA521420953B1 (ar) | بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1 | |
| CO2019006565A2 (es) | Novedoso conjugado de amanitina | |
| EA202092202A1 (ru) | Конструкции антител к ror | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| CR11374A (es) | Proteinas humanas de union a antigenos del gm-csf | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
| EA202092849A1 (ru) | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение | |
| PE20221760A1 (es) | Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos | |
| MX2023000547A (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas. | |
| MX2024011985A (es) | Proteinas de union multiespecificas que se unen a dectin-1 y cd20 y metodos de uso de las mismas | |
| CO2023010689A2 (es) | Anticuerpos y usos de estos | |
| CR20210094A (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) | |
| CL2022003161A1 (es) | Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2. | |
| MX2022000654A (es) | Sistemas fluorescentes para imagenes biologicas y usos de los mismos. | |
| CR20240489A (es) | Agentes aglutinantes 5t4 y usos de los mismos | |
| MX2024011128A (es) | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. |